ANVISA’s new 2025 manual for health-use materials registration establishes strict new standards for medical device submissions in Brazil, aligned with RDC 751/2022. By enforcing a “summary rejection” policy for incomplete dossiers and clarifying digital submission rules, the agency aims to eliminate regulatory queues and accelerate market access for compliant manufacturers.
Brazil, December 30, 2025 — ANVISA has released its comprehensive Manual for Registration of Materials for Use in Health, providing critical updated guidance for manufacturers and importers of medical devices in Brazil. The manual compiles regulatory requirements under RDC 751/2022, explicitly aiming to standardize dossier information and reduce the inconsistencies that frequently lead to technical requirements or outright rejections. For companies targeting the Brazilian market, understanding these new “zero-tolerance” submission rules is essential to avoid delays.
KEY UPDATES IN ANVISA 2025 MANUAL FOR BRAZIL MEDICAL DEVICE REGISTRATION
The new manual consolidates current regulatory requirements and introduces stricter compliance checks, including:
- The “One Strike” Rule (Summary Rejection): ANVISA has clarified that insufficient technical documentation at the time of filing will now lead to summary rejection (indeferimento sumário) rather than a request for additional information. This applies if mandatory documents from the checklist are missing.
- Mandatory 6-Chapter Dossier Structure: Technical dossiers for Class III and IV devices must now follow a strict structure:
- Chapter 1: Administrative & Technical Forms.
- Chapter 2: Product Description & Global Marketing History.
- Chapter 3: Essential Safety & Performance (Risk Management, Stability).
- Chapter 4: Clinical Evidence (Clinical Evaluation Reports).
- Chapter 5: Labels & Instructions for Use.
- Chapter 6: Manufacturing Flowcharts.
- Chapter 1: Administrative & Technical Forms.
- Digital-Only Submission Standards: All submissions must be made via the Solicita System or Electronic Petitioning System. Documents must be signed using Qualified Digital Signatures (ICP-Brasil) or gov.br Advanced Electronic Signatures; scanned paper signatures are no longer accepted.
- Optimized Analysis (Reliance): The manual explicitly outlines the pathway for using approvals from foreign authorities (AREE) like the US FDA or Health Canada to fast-track analysis for Class III and IV devices.
IMPACT OF ANVISA 2025 ON BRAZIL'S MEDICAL DEVICE SECTOR
The manual is designed to improve predictability and transparency in ANVISA’s review process by:
- Reducing the Regulatory Queue: By enforcing higher quality initial submissions, ANVISA aims to contribute to its strategic project of reducing review queues and increasing speed.
- Eliminating Inconsistencies: The guidance seeks to standardize information across dossiers, reducing the volume of “technical requirements” (questions from reviewers) that slow down approvals.
- Clarifying High-Risk Requirements: Specific attention is given to Class III and IV devices, ensuring that clinical evidence and risk management data are presented in a format that allows for faster evaluation.
HOW COMPANIES CAN COMPLY WITH ANVISA'S 2025 REGISTRATION RULES
To align with the new manual and avoid summary rejection, companies should:
- Audit Digital Signatures: Ensure all Legal and Technical Representatives possess valid ICP-Brasil or gov.br digital signatures before petitioning.
- Verify Document Completeness: Rigorously check all documents against the ANVISA checklist before protocol. Missing a single mandatory document will result in immediate rejection without a chance to correct it.
- Adopt the 6-Chapter Format: Restructure internal technical files to match the specific 6-chapter organization mandated for the Technical Dossier.
- Leverage Foreign Approvals: For eligible Class III and IV devices, utilize the Optimized Analysis procedure by submitting proof of approval from recognized foreign regulators (AREE) to expedite the process.
External links: